Announcements
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
- ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
- ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
- ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
- ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
More ▼
Key statistics
As of last trade, Oric Pharmaceuticals Inc (4TZ:DUS) traded at 8.00, 81.82% above the 52 week low of 4.40 set on May 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.00 |
---|---|
High | 8.00 |
Low | 8.00 |
Bid | 8.00 |
Offer | 8.35 |
Previous close | 8.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 67.38m |
Free float | 60.96m |
P/E (TTM) | -- |
Market cap | 587.52m USD |
EPS (TTM) | -1.97 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 11:32 BST.
More ▼